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ABSTRACT
Current chemotherapy of cutaneous leishmaniasis (CL), even the mildest forms, encompasses multiple and
painful injections with toxic drugs that cause systemic adverse effects. Recently, we showed the promising use
of poly(lactic-co-glycolic acid) (PLGA) microparticles loaded with an antileishmanial nitrosylated chalcone (CH8)
for effective, safe, local, and single-dose treatment of CL. Here, we proposed to optimize the delivery system
by increasing the CH8 loading in PLGA-microparticles using spray drying instead of emulsification-solvent
evaporation. The effect of solvent composition and polymeric matrix changes on thermal properties, loading
efficiency, particle size, morphology, and spatial drug distribution of the CH8-loaded microparticles was eval-
uated. The results showed that spray drying allowed a higher CH8 content (18% w/w), as contrasting with the
previous solvent evaporation technique that maximally incorporated 7.8% of CH8. In vitro studies on 96-hour
incubation with L. amazonensis-infected macrophages showed that entrapment in spray-dried PLGA micropar-
ticles rendered CH8 safer, preserved its antileishmanial activity, and did not affect its antioxidant properties.
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Introduction
Leishmaniasis is a complex of disease caused by the infection with
the protozoan parasites of the genus Leishmania that are transmitted
by the bite of phlebotomine sandflies. Cutaneous leishmaniasis (CL) is
a dermal disorder witch cause high morbidity levels with a wide spec-
trum of clinical manifestations [1,2]. This disease is widespread in the
world with approximately 0.7 to 1.2 million cases each year [3]. The
first choice for CL treatment is the pentavalent antimonial drugs used
since 1960’s. Pentamidine, amphotericin B, and paromomycin are con-
sidered as second choice drugs. However, all these available drugs
can present hazardous side effects, emergence of drug-resistant, and
variable efficacy in different geographic areas and Leishmania species
[1,4]. The search for new drugs is urgently needed.
Different studies have been appointed chalcones and their
derivatives as potential drug candidates for leishmaniasis treat-
ment [5–9]. A new chalcone derivate, 3-nitro-2’-hydro-4’,6’-
dimethoxychalcone (CH8) synthesized and patented by our group
has shown a promising activity against both promastigotes and
intracellular amastigotes of Leishmania amazonensis. In a murine
model of cutaneous leishmaniasis the CH8 displayed the same effi-
cacy of the reference drug (PentostanVR ) in a dose 10 times lower [6].
To be successful, the treatment of CL should be effective with
low doses, local effect, and safe [10]. Intralesional antimonial
administration has been explored and demonstrated a good effect,
although this treatment is based on multiple injections that induce
local pain and may cause side effects, like anaphylactic shock
[11,12]. Topical treatments are an attractive alternative due to eas-
ier administration, lower side effects, and patient-compliance.
Nonetheless most of the studies using topical formulations with
paromomycin and amphotericin B presented low efficacy, due to
their poor permeability through the skin, which need the use of
permeation enhancers that promote an irritant effect and hamper
their approval [10,13–15].
Another interesting alternative for the local treatment of CL is
the use of drug delivery systems. The polymeric implants systems
have the advantages such as local action, reduced side effects, and
improved patient compliance [16]. In leishmaniasis the implants
based on microparticles can be up taken by macrophages, the
main cell infected, which potentiate the drug effect [17]. Poly(lactic-
co-glycolic acid) (PLGA) implants are extensively applied in the clin-
ical field due to their biocompatibility and biodegradability. Fifteen
PLGA implants have been already approved by FDA from which, 11
are based on microparticles with applications in different diseases
[18]. However, PLGA microparticle implants are poorly explored for
the local treatment of CL.
Recently our group produced a PLGA microparticle implant
loaded with 7.8% of CH8 prepared by emulsion-solvent evaporation
method. This formulation administrated in a single dose by intrale-
sional route demonstrated the same efficacy than the free drug in
three doses in mice infected with L. amazonensis [19]. However, the
emulsion-solvent evaporation method has many process variables
that can hinder the scale up. In addition, we believe that the
increase of the drug load in the microparticle implant can improve
its effectiveness in a single dose and reduce the treatment cost with
lowers amounts of polymer per dose. The goal of this study was to
increase the CH8 load in implant based on PLGA microparticles gen-
erated by spray drying as an alternative production method. The
effect of some parameters such as the composition of the polymeric
matrix and the type of solvent was studied in the present work.
Materials and methods
Materials
The following chemicals were used as received: PLGA 5004 (lactide–
glycolide molar ratio of 50:50, inherent viscosity of 0.41dl/g)
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was purchased from PURAC Biomaterials (Gorinchem, The
Netherlands); polyvinylpyrrolidone K17 (PVP K17) (Kollidon_17PF
endotoxinfree, BASF AG, Ludwigshafen, Germany); dichloromethane
(DCM - Sigma-Aldrich, St. Louis, MO); ethyl acetate (EA - Fluka); aceto-
nitrile (Sigma-Aldrich); phosphoric acid (FlukaTM, Seelze, Germany).
The synthetic Chalcone 3-nitro-2-hidroxi-4,6-dimetoxichalcona was
prepared as previously shown and patented by our group [6,20].
Solubility parameter estimation
The Hansen solubility parameter (d) [21] was used to estimate the
affinity between CH8 and PLGA, and PVP polymers and improved
understanding of polymer effects in the final solid state of spray-
dried microparticles. The Hansen solubility parameter was calcu-
lated from the chemical structures of CH8, PLGA, and PVP using
the Hoftyzer and Van Krevelen group contribution method [22]
according to Equation (1):
d ¼ ðd2d þ d2p þ d2hÞ1=2 (1)
where:
dd ¼
P
iFdi
V
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V is the molar volume and Fdi, Fpi, and Ehi are the group contribu-
tions for the different types of interactions (dispersion forces, polar
interactions, and hydrogen bonding, respectively), which are
reported in the literature [21].
Preparation of CH8-loaded polymeric microparticles
CH8-loaded polymeric microparticles were prepared using a Buchi
B-290 spray-dryer (Buchi Labortechnik AG, Flawil, Switzerland)
equipped with Inert Loop B-295 and an integrated two-fluid 2mm
nozzle. Compressed nitrogen dispersed the liquid into fine drop-
lets, which were consequently dried in the drying chamber and
deposed in the cyclone. Drying conditions are given as follows for
all prepared samples: aspirator 85%; pump flow rate 360ml/h and
compressed nitrogen flow rate 500 l/h. The inlet temperature was
set to 49 ± 1 %C and the resultant outlet temperature was 38 ± 2 %C.
The experiments were made in duplicate.
The drug:polymer mass proportion (dry basis) was fixed at 1:5.
PLGA alone or a mixture of PVP K17 and PLGA of 1:10 were used.
The feeding solution was prepared by dissolving CH8 in a 1.5%
(w/v) solution of PLGA or PLGA/PVP K17 in dichloromethane or in a
mixture of ethyl acetate in dichloromethane (1:2).
The individual polymers were also spray-dried from organic sol-
utions. They were used for comparison purposes. All obtained
powders were collected in glass containers and stored at &20 %C
before further studies.
CH8-loaded polymeric microparticles were also produced by
emulsification-solvent evaporation method. The preparation proto-
col was previously described by our group [19]. In our previous
studies, a maximum CH8 loading of 7.8% was obtained by following
this experimental protocol. The aim is to compare the performance
of the CH8-loaded PLGA microparticles prepared by the two differ-
ent processes, spray drying and emulsion-solvent evaporation.
Table 1 summarizes all studied formulations.
Physico-chemical characterization of the CH8-loaded polymeric
microparticles
Thermal analyses
Thermal analyses were performed using a differential scanning
calorimeter DSC Q2000 with the base module and modulate-DSC (TA
Instruments, Leatherhead, UK). Samples were heated in non-hermetic
aluminum pans at a rate of 5 %C/min from 15 to 200 %C under nitro-
gen flow of 50ml/min using an empty sealed pan as reference. DSC
modulated technique (mDSC) was used to increase the resolution
and the sensibility for weak transitions. In mDSC experiments, the
samples were heated by a sinusoidal program of 2 %C/min from 20
to 150 %C, with the modulation period of 40 s and amplitude 0.8 %C.
Drug loading
Drug loading was determined by dissolving 2mg of PLGA or
PLGA/PVP microparticles in 5ml of acetonitrile and analyzing the
sample using high-performance liquid chromatography (HPLC).
HPLC was performed on an Agilent chromatographic system
(1100, Agilent), and a Grace C18 column (250' 4.6mm 5mm –
201TP54, Grace, Munich, Germany). Acetonitrile: phosphoric acid
0.01% in water (80:20, v/v) was used as the mobile phase at
a flow rate of 1.0ml/min. The ultraviolet detection was conducted
at 337 nm. Data was analyzed using the ChemStation software
(Agilent, Palo Alto, CA). The calibration curve was
Table 1. Formulation parameters and thermal analysis (DSC) of the polymeric particles prepared by spray drying and
by emulsion-solvent evaporation methods.
Code formulation Polymer Solvent
Particles characteristics
Size (mm)
Percentage CH8 loaded
Thermal properties
D10 D50 D90 Span Tg (%C) Tmonset (%C)
Spray drying method
Blank (polymeric) particles
PD PLGA DCM 1.93 10.19 22.71 2.04 – 45.4 –
PDE PLGA DCM:EA 1.46 6.21 16.63 2.44 – 46.3 –
VD PVP DCM – – – – – 145.5 –
PVD PLGA:PVP DCM 2.13 5.30 14.47 2.33 – 45.9 –
PVDE PLGA:PVP DCM:EA 1.88 4.35 12.18 2.37 – 48.1
154.0
–
CH8-loaded (polymeric) particles
CH8/PD PLGA DCM 2.69 12.34 25.82 1.87 18.34 ± 0.02 38.4 134.6
CH8/PVD PLGA:PVP DCM 1.58 5.75 12.82 1.96 17.82 ± 0.04 40.9 136.0
CH8/PDE PLGA DCM:EA 1.53 8.40 17.99 1.96 18.10 ± 0.01 38.5 141.7
CH8/PVDE PLGA:PVP DCM:EA 1.66 8.97 19.11 1.95 18.14 ± 0.02 38.5 139.2
Emulsion-solvent evaporation method
CH8-loaded (polymeric) particles
CH8/PLGA PLGA DCM 0.60 5.49 13.40 2.30 7.84 ± 1.50 48.6 150.5
y¼ 51.75xþ 410.6 (r¼ 0.9992, n¼ 3), which exhibited linearity over
a concentration range of 50–300 lg/ml of CH8. The drug loading
was calculated by the following Equation (2):
Drug loading %ð Þ ¼ Weight of drug in spray&Dried microparticles
Weight of spray & Dried microparticles ' 100% (2)
Size, morphology and drug distribution within the CH8-loaded
polymeric microparticles
Particle size was determined by laser light scattering (Mastersizer
2000, Malvern, Worcestershire, UK) using a Fraunhofer diffraction
model for the analysis of the raw data. The particles were dispersed
in 0.5% (w/w) Tween-20 solution and subsequently treated with
ultrasound for 20 s (20 kHz, 50W) [23]. Particle diameter was
expressed as the values of D90, D50, and D10, where 90th, 50th,
and 10th percent of the population lies below this value. Polydispersity
was given by span index, calculated by (D90 –D10)/D50.
The morphology and the surface structure were assayed by field
emission gun scanning electron microscopy (FEG-SEM) using Philips
XL30 ESEM-FEG instrument (Philips, Eindhoven, Netherlands) operating
at an acceleration voltage of 20 kV under nitrogen atmosphere. The
microparticles were fixed on an aluminum stub using double-sided
carbon tape and was coated by sputtering with gold for four minutes
at 18,000mA using a Polaron SC7640 (Quorom Technology, England).
The drug distribution in the spray-dried microparticles was
mapped by Raman microscopy (Alpha 300R Raman-AFM spectropho-
tometer, WITEC GmbH, Germany). The spectra were obtained at room
temperature and 50X magnification using a confocal laser wavelength
of 532nm (Nd:YAG laser) and ultrahigh-throughput (UHTS 300) spec-
troscopy system with a CCD charge-coupled device (CCD) as detector.
Each spectral scan was collected for 0.5 s of integration using ten
accumulations and each sample was analyzed three times.
Biological evaluation
Antileishmanial activity
The antileishmanial activity of CH8-loaded polymeric microparticles
was evaluated against intracellular amastigote of L. amazonensis
(Josefa strain). Adherent mouse peritoneal macrophages (5' 105
cells) were plated on coverslips and infected with 5' 106 promas-
tigotes for 4 h at 34 %C, after which non-internalized parasites were
removed with warm phosphate buffered saline (PBS). Then, to
allow for intracellular amastigote growth, the cells were cultured
for a further 24 h at 37 %C in Roswell Park Memorial Institute
medium (RPMI) supplemented with 5% heat-inactivated fetal
bovine serum (HIFBS, Cultilab, Brazil).
Next, the infected macrophages were treated for 96h in triplicates
with a range of concentrations (0.5, 5, and 50mg/ml) of free CH8 or
CH8 encapsulated in microparticles produced by spray drying (CH8/
PDE and CH8/PVDE) or emulsification-solvent evaporation (CH8/
PLGA). At the end of treatment time, the cell monolayers were
stained with Giemsa and the numbers of amastigotes in total 200
macrophages per coverslip were counted in Neubauer chambers. The
results were expressed both as amastigotes per 100 macrophages
and IC50 (drug concentration that inhibited parasite growth by 50%).
Anti-macrophage cytotoxicity
The ‘resazurin reduction test’ is a very simple and versatile way to
measure cell cytotoxicity. This method is based on the enzymatic
reduction of resazurin sodium salt (blue and nonfluorescent) to
resorufin (pink and highly fluorescent) by metabolically active cells
[24]. For evaluation of the anti-macrophage cytotoxicity,
macrophages were infected and treated for 96 h with CH8 encap-
sulated or not, as described above for antileishmanial activity.
Then, 10% (v/v) of resazurin solution (0.125mg/ml;Sigma-Aldrich)
was added in the medium and cells were cultured for additional
four hours at 37 %C. Following incubation, the fluorescence was
measured at 555/585 nm (Bio-Tek Powerwave XS, Winooski, VT).
The results were reported as the percentage of viable cells normal-
ized to untreated cells. The 50% cytotoxic concentration (CC50) val-
ues were determined by logarithmic regression analysis.
Nitric oxide (NO) production
The NO induction by microparticles was assessed in both unin-
fected and L. amazonensis-infected macrophages, as described
for antileishmanial activity. After 24 h of infection, the cells
were treated for additionally 96 h with CH8 encapsulated or not
(50 mg/ml) or equivalent amounts of blank microparticles. As con-
trols untreated cells and 1mg/ml of lipopolysaccharide (LPS
Escherichia coli, Sigma-Aldrich)-treated cells were used. The stable
sodium nitrite (NaNO2) product was measured in the culture
supernatants at 570 nm (BIO-TEK, Powerwave XS) by Griess colori-
metric method and NaNO2 standard curve [25].
Statistical analysis
Unpaired t test with Welch’s correction was performed to demon-
strate statistical differences (p< .05) between two groups. IC50 val-
ues were calculated from a curve of sigmoidal dose-response. All
analysis were conducted using GraphPad Prism 5 software
(GraphPad Software, La Jolla, CA).
Results and discussion
Physicochemical characterization of CH8-loaded polymeric
microparticles
Thermal properties
All heating curves obtained from DSC analyses are grouped in Figure 1,
including the heating curve of a physical mixture between CH8
and PLGA in a mass proportion of 1:2. The thermal profile of
unprocessed CH8 crystals shows a distinct melting endotherm
(Tmonset) at 166.3 %C with a DHm of 89.21 J/g. Amorphous PLGA has
a glass temperature (Tg) in the range of 45.4–46.3 %C (PD and PDE,
respectively), whereas spray-dried PVP has a Tg of 145.5 %C (VD).
The fast solvent evaporation of solvents from organic solutions
containing two dissolved constituents, drug and polymer, in most
cases leads to the formation of amorphous solids dispersions during
spray drying [26]. An amorphous solid dispersion constituted of CH8
and PLGA or PLGA/PVP could be theoretically expected from the
analysis of their molecular structure and solubility parameters (d).
The solubility parameters (d) for CH8 from its molecular division in
groups was calculated to be 21.9MPa1/2. The dt calculated values for
PLGA (24.36MPa1/2) and PVP (23.36MPa1/2) are close to data found
in the literature [21,27,28]. It is generally believed that favorable
interactions and a uniform phase will result when the difference in
dt values between two components (Ddt) is less than 7MPa1/2, while
unfavorable interactions and phase separation will result when Ddt
> 10MPa1/2 [29]. In the present case, Ddt between CH8 and all poly-
mers used is lower than 3MPa1/2 and CH8 is likely to be miscible
with these polymers in the spray-dried microparticles.
However, despite the favorable outcome in the Ddt, the spray-
dried CH8-loaded polymeric microparticles are not constituted by
a homogeneous mixture of amorphous components. In fact, from
the DSC results (Table 1), all CH8 loaded-polymer particles present
a clear Tg corresponding to the Tg of the polymers and in add-
ition a melting endotherm near to the melting point (Tm) of the
CH8 crystalline form. The presence of the polymers in the spray-
dried microparticles led to a depression in the melting point of
the drug in the binary mixtures. This finding could be indicative of
mixing between two components, as already found and discussed
in the literature for other binary mixtures of drug and polymer
[30]. In theory, melting of a crystal occurs at the temperature
when the chemical potential of the crystal is equal to the chemical
potential of the melt. Addition of an amorphous polymer to the
crystal (if miscible) reduce the chemical potential of the crystalline
material leading to the reduction of its melting temperature [31].
DCM alone and a mixture of DCM:EA (1:2) were used as sol-
vents for drug and polymers. The influence of the initial solvent
composition on the thermal properties of the spray-dried micro-
particles can be observed with a lower depression of Tm when
DCM was used as solvent (Table 1). PLGA is less soluble in EA
than in DCM, probably the lower solubility of PLGA in the mixtures
DCM:EA led to a more rapid precipitation of the polymer interfer-
ing in drug-polymer interaction.
Another investigation carried out in this study was the intro-
duction of PVP (10% w/w) in the polymeric matrix. PVP is a bio-
compatible and hydrophilic polymer, capable of promoting the
formation of solid amorphous dispersions by forming electrostatic
interactions with several drugs [32]. Irrelevant differences were
observed in the Tm of the drug in spray-dried PLGA microparticles
containing PVP in the polymeric matrix compared to the CH8-
loaded PLGA microparticles without PVP (Table 1).
Drug loading efficiency
The spray-dried CH8-loaded polymeric microparticles covered an
actual drug loading range of 17.8 to 18.3% w/w, compared to
7.8% w/w for the microparticles obtained by emulsion-solvent
evaporation (Table 1). The changes in the polymeric matrix or
solvent composition did not significantly modify the high drug
loading efficiency (>96%) for the spray-dried microparticles.
Particle size, morphology, and spatial drug distribution
Despite of all modifications in the spray-dried formulations, the par-
ticle size ranged from 1.5 (D10) to 26mm (D90; Table 1), in a very
close way. In comparison, CH8-loaded PLGA microparticles prepared
by emulsion and solvent evaporation showed a smaller size range
(from 0.6 (D10) to 13.4mm (D90). This variety in the microparticle
distribution size is interesting because the microparticles below
10mm can be efficiently uptake by macrophages [33], the main cell
infected in leishmaniasis, while the largest were desired to obtain
injectable microparticles for depot applications [34,35].
All particles were analyzed by FEG-SEM and showed a similar
topography. Figure 2 depicts a representative picture of PLGA
microparticles loaded with CH8 showing that they are spherical and
Figure 1. DSC thermograms. (A) Blank microparticles (PVDE; PVD; VD; PDE, and PD); (B) CH8’s microparticles produced by spray drying (CH8/PVDE; CH8/PDE; CH8/PVD,
and CH8/PD) and by emulsion-solvent evaporation (CH8/PLGA) methods, unprocessed CH8 crystals (CH8) and physical mixture between CH8 and PLGA was in a mass
proportion of 1:2 (CH8þ PLGA).
Figure 2. SEM micrograph of PLGA microparticles with CH8. (A) Intact particles; (B) Particles rubbed out by friction, showing the inside with crystal shapped CH8 chal-
cone (white arrows).
have a relatively smooth surface (Figure 2(A)). The intentional wear
in the surface of the particles revealed an interior probably rich in
drug crystals (Figure 2(B)). To confirm this statement, the spatial dis-
tribution of components inside the microparticles was evaluated by
RAMAN microscopy mapping. For this, surface (20' 20lm) and
deep spectra (9' 9lm) have been taken for accuracy.
RAMAN microcopy has been used to study the distribution of
drugs in drug delivery systems without the need to mark the mol-
ecule [36]. Our results confirmed that CH8 loaded-polymeric micro-
particles have an outer phase composed of a mixture of drug and
polymer (peaks around 1600 cm&1 of CH8 and peaks between 2800
and 3200 cm&1 of PLGA or PLGA/PVP) and an inner phase where
the drug predominates (Figure 3). All particles studied showed the
same polymer and drug distributions, although it was not possible
to differentiate the PLGA and PVP spatial distributions, because of
their similar spectra with mean peaks between 2800 and 3200 cm&1.
No changes were observed in the microparticles characteristics,
even though the physical composition of the microparticles were
altered. The microparticles produced with DCM:EA as solvent
phase was chosen to continue the in vitro experiments, because
they were produced with a lower ratio of DCM in the feed solu-
tion, creating a more sustainable method.
Biological evaluation of the CH8-loaded PLGA microparticles
Antileishmanial activity
All CH8 formulations were active against intracellular amastigotes
of L. amazonensis. As demonstrated before, encapsulation of CH8
in PLGA microparticles preserved the CH8 antileishmanial activity
[19] and the addition of PVP in the polymeric matrix did not
modify this effect. Nonetheless, encapsulation of CH8 into micro-
particles slightly increased its IC50 from 0.4mg/ml (free CH8) to
0.9–1.9 mg/ml (CH8 loaded polymeric microparticles), as shown
in Figure 4. That is probably due to the slow drug release
from microparticles in the intracellular milieu. The process that led
to higher CH8/PLGA activity was emulsification-solvent evapor-
ation (IC50¼ 0.9mg/ml), as compared with spray drying (CH8/
PVDE: 1.8mg/mL and CH8/PDE: 1.9mg/ml). Since CH8/PLGA
Figure 4. Antiamastigote activity. L. amazonensis-infected macrophages were
treated with free or encapsulated CH8 (0; 0.5; 5, and 50mg/ml) or left untreated
for 96 h at 37 %C. The intracellular amastigote loads, in total 100 macrophages/
coverslip, were counted in Giemsa-stained cells. The half maximal inhibitory con-
centration (IC50) values were determined by logarithmic regression analysis.
Means ± SD (n¼ 3).
Figure 3. Representative Raman mapping of the microparticles with peaks of CH8 (peaks around 1600 cm&1) and PLGA (peaks between 2800 and 3200 cm&1) in the
surface (20' 20lm) and deep spectra (9' 9lm).
microparticles can be efficiently internalized by macrophages [19],
the higher CH8/PLGA activity may be related to its higher uptake
by macrophages due to the smaller size.
Anti-macrophage cytotoxicity
PLGA microparticles are widely used in different FDA-approved
products, supporting their safety [18,37]. CH8 safety and antileish-
manial activity have also been described [6]. However, in this
work, the safety of their formulation was evaluated. Despite of the
high antileishmanial activity of CH8, cytotoxicity was observed in
higher concentrations of these drug [19]. Our in vitro studies on
96-hour incubation with L. amazonensis-infected macrophages
showed that all CH8-loaded microparticles tested (CH8/PLGA, CH8/
PDE, and CH8/PVDE) displayed higher safety than free CH8
(CC50>50 and 36.8mg/ml, respectively; Figure 5). The slight
decrease in cell viability observed in CH8-loaded polymeric micro-
particles may be a drug effect, since blank microparticles (with or
without PVP) did not modify cell viability.
NO production
Macrophage microbicidal mechanisms such as reactive oxygen spe-
cies (ROS) and NO production play an important role in the control
of Leishmania infection [38,39]. It is also known that NO induction
directly correlates with decreased parasite loads in patients with
cutaneous leishmaniasis [40]. Additionally, endocytosis itself may
induce physical changes in the plasma membrane, which culmi-
nates with the activation of nitric oxide synthase and NO gener-
ation [17]. Then, to verify if the microparticle uptake interfered with
oxidative mechanisms, NO production was evaluated in infected
and uninfected macrophages following addition of free or
encapsulated CH8 to cells. However, no NO production was induced
(Figure 6) and was also seen to be compatible with the antioxidant
[41] and anti-inflammatory properties of chalcones, even with a
decrease in NO production [42,43]. In all, these results show that
PLGA microparticles do not revert the antioxidative mechanisms of
CH8 in macrophages. So, the CH8-microparticles antileishmanial
activity was due to the direct action of the intracellularly released
CH8 and was not to due to the macrophage activation, compatible
with the direct action of CH8 in the Leishmania mitochondria [5,8].
Conclusion
Alternative treatments of CL using safer drugs and reduced doses
are urgently need. Polymeric implants emerge as an attractive strat-
egy to solve this problem. However, to the best of our knowledge,
this is the first attempt to develop chalcone implant based on
spray-dried PLGA microparticles. In the current work, spray drying
allowed the efficiently production of CH8 loaded-PLGA micropar-
ticles with an increase around 125% in the CH8 chalcone content in
relation to the microparticles obtained previously by an emulsion-
solvent evaporation process. Besides, in our in vitro studies, the
CH8-microparticles showed to be safe and active against Leishmania
amazonensis amastigotes. In future studies, we propose to evaluate
in vivo the efficacy and safety of encapsulated CH8 in experimental
models of cutaneous leishmaniasis.
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